Malignant Leptomeningeal Neoplasm
Associated Genetic Biomarkers
NCI Definition: A primary or metastatic malignant tumor involving the leptomeninges. 
There are 2 clinical trials for malignant leptomeningeal neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain malignant leptomeningeal neoplasm as an inclusion criterion, 2 are phase 1 (2 open).
CD276 and MSLN are the most frequent gene inclusion criteria for malignant leptomeningeal neoplasm clinical trials .
Amg 994, iodine i 131 omburtamab, and zeluvalimab are the most common interventions in malignant leptomeningeal neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.